- Home
- KYMR
as 07-26-2024 4:00pm EST
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
Upcoming Earnings Alert:
Get ready for potential market movements as Kymera Therapeutics Inc. KYMR prepares to release earnings report on 01 Aug 2024.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 2.6B | IPO Year: | 2020 |
| Target Price: | $42.09 | AVG Volume (30 days): | 813.1K |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.60 - $48.70 | Next Earning Date: | 08-01-2024 |
| Revenue: | $79,413,000 | Revenue Growth: | 70.16% |
| Revenue Growth (this year): | -32.3% | Revenue Growth (next year): | 29.28% |
Stock Insider Trading Activity of Kymera Therapeutics Inc. (KYMR)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gollob Jared | KYMR | Chief Medical Officer | Jul 15 '24 | Sell | $46.10 | 9,864 | $454,695.88 | 95,470 | SEC Form 4 |
| Gollob Jared | KYMR | Chief Medical Officer | Jul 15 '24 | Sell | $45.59 | 13,281 | $605,521.96 | 105,604 | SEC Form 4 |
| Gollob Jared | KYMR | Chief Medical Officer | Jul 15 '24 | Sell | $45.15 | 16,455 | $742,925.15 | 95,740 | SEC Form 4 |
| Booth Bruce | KYMR | Director | Jun 12 '24 | Sell | $34.98 | 1,770 | $61,914.60 | 802,022 | SEC Form 4 |
| Booth Bruce | KYMR | Director | Jun 12 '24 | Sell | $34.98 | 8,430 | $294,881.40 | 4,548,400 | SEC Form 4 |
| Booth Bruce | KYMR | Director | Jun 12 '24 | Sell | $36.02 | 420 | $15,128.40 | 803,792 | SEC Form 4 |
| Booth Bruce | KYMR | Director | Jun 12 '24 | Sell | $35.35 | 2,485 | $87,844.75 | 804,212 | SEC Form 4 |
| Booth Bruce | KYMR | Director | Jun 12 '24 | Sell | $36.02 | 1,997 | $71,931.94 | 4,556,830 | SEC Form 4 |
| Booth Bruce | KYMR | Director | Jun 12 '24 | Sell | $35.35 | 11,838 | $418,473.30 | 4,558,827 | SEC Form 4 |
| Horobin Joanna | KYMR | Director | Jun 7 '24 | Sell | $33.11 | 6,313 | $209,005.12 | 0 | SEC Form 4 |
| Horobin Joanna | KYMR | Director | Jun 7 '24 | Sell | $32.65 | 2,187 | $71,394.83 | 6,313 | SEC Form 4 |
| Chadwick Jeremy G | KYMR | Chief Operating Officer | May 23 '24 | Sell | $34.99 | 2,575 | $90,104.66 | 44,183 | SEC Form 4 |
| Booth Bruce | KYMR | Director | Mar 14 '24 | Sell | $39.73 | 34,473 | $1,369,612.29 | 4,641,602 | SEC Form 4 |
| Booth Bruce | KYMR | Director | Mar 14 '24 | Sell | $40.66 | 10,846 | $440,998.36 | 4,630,756 | SEC Form 4 |
| Booth Bruce | KYMR | Director | Mar 14 '24 | Sell | $41.51 | 781 | $32,419.31 | 4,629,975 | SEC Form 4 |
| Booth Bruce | KYMR | Director | Mar 14 '24 | Sell | $39.73 | 7,292 | $289,711.16 | 821,538 | SEC Form 4 |
| Booth Bruce | KYMR | Director | Mar 14 '24 | Sell | $40.66 | 2,233 | $90,793.78 | 819,305 | SEC Form 4 |
| Booth Bruce | KYMR | Director | Mar 14 '24 | Sell | $41.51 | 154 | $6,392.54 | 819,151 | SEC Form 4 |
| Booth Bruce | KYMR | Director | Mar 14 '24 | Sell | $39.31 | 8,126 | $319,433.06 | 4,621,849 | SEC Form 4 |
| Booth Bruce | KYMR | Director | Mar 14 '24 | Sell | $40.62 | 49,591 | $2,014,386.42 | 4,572,258 | SEC Form 4 |
| Booth Bruce | KYMR | Director | Mar 14 '24 | Sell | $41.23 | 1,593 | $65,679.39 | 4,570,665 | SEC Form 4 |
| Booth Bruce | KYMR | Director | Mar 14 '24 | Sell | $39.31 | 1,714 | $67,377.34 | 817,437 | SEC Form 4 |
| Booth Bruce | KYMR | Director | Mar 14 '24 | Sell | $40.62 | 10,411 | $422,894.82 | 807,026 | SEC Form 4 |
| Booth Bruce | KYMR | Director | Mar 14 '24 | Sell | $41.23 | 329 | $13,564.67 | 806,697 | SEC Form 4 |
| Booth Bruce | KYMR | Director | Mar 11 '24 | Sell | $42.84 | 1,386 | $59,376.24 | 828,830 | SEC Form 4 |
Latest Kymera Therapeutics Inc. News
KYMR Breaking Stock News: Dive into KYMR Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
We're Not Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn
Zacks
15 days ago
Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
Zacks
17 days ago
Kymera Therapeutics (KYMR) Surges 23.4%: Is This an Indication of Further Gains?
Motley Fool
17 days ago
Why Kymera Therapeutics Stock Is Soaring Today
Investing.com
17 days ago
Kymera Therapeutics soars as Sanofi expands phase 2 trials
Investopedia
17 days ago
Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug
Zacks
17 days ago
Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies
MT Newswires
18 days ago
B. Riley Adjusts Price Target on Kymera Therapeutics to $36 From $31, Maintains Neutral Rating
Compare KYMR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KYMR Kymera Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.